Yunda Huang

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials
    Yunda Huang
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA Department of Global Health, University of Washington, 1510 San Juan Rd, Seattle, WA 98195, USA Electronic address
    Vaccine . 2017
  2. pmc Use of placebos in Phase 1 preventive HIV vaccine clinical trials
    Yunda Huang
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Electronic address
    Vaccine 33:749-52. 2015
  3. pmc Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error
    Yunda Huang
    Statistical Center for HIV AIDS Prevention and Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Stat Med 31:3748-59. 2012
  4. pmc Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials
    Nicholas Shulman
    LabKey Software Foundation, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cytometry A 73:847-56. 2008
  5. pmc Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)
    Ann Duerr
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109 1024, USA
    J Infect Dis 206:258-66. 2012
  6. pmc HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable
    Stephen C De Rosa
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA
    J Immunol 187:3391-401. 2011
  7. pmc Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine
    Nicole Frahm
    Vaccine and Infectious Disease Division and HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Clin Invest 122:359-67. 2012
  8. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study
    Yunda Huang
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 9:e108631. 2014
  9. pmc Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
    Yunda Huang
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 10:e0136626. 2015
  10. pmc New clinical trial designs for HIV vaccine evaluation
    Zoe Moodie
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Curr Opin HIV AIDS 8:437-42. 2013

Detail Information

Publications18

  1. pmc Predictors of durable immune responses six months after the last vaccination in preventive HIV vaccine trials
    Yunda Huang
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA Department of Global Health, University of Washington, 1510 San Juan Rd, Seattle, WA 98195, USA Electronic address
    Vaccine . 2017
    ..In this paper, we investigated whether and how baseline demographic variables and immune responses measured two weeks after vaccination predicted durable immune responses measured six months later...
  2. pmc Use of placebos in Phase 1 preventive HIV vaccine clinical trials
    Yunda Huang
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Electronic address
    Vaccine 33:749-52. 2015
    ..In some settings, however, placebo recipients are less important because other data sources and tools are available to achieve the study objectives. ..
  3. pmc Comparing and combining data across multiple sources via integration of paired-sample data to correct for measurement error
    Yunda Huang
    Statistical Center for HIV AIDS Prevention and Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Stat Med 31:3748-59. 2012
    ..We illustrate our methods using real enzyme-linked immunosorbent spot assay data generated by two HIV vaccine laboratories...
  4. pmc Development of an automated analysis system for data from flow cytometric intracellular cytokine staining assays from clinical vaccine trials
    Nicholas Shulman
    LabKey Software Foundation, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cytometry A 73:847-56. 2008
    ..Routine use of the system does not require specialized expertise. This high-throughput analysis will provide great utility for rapid evaluation of complex multiparameter flow cytometric measurements collected from large clinical trials...
  5. pmc Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)
    Ann Duerr
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109 1024, USA
    J Infect Dis 206:258-66. 2012
    ..Follow-up was extended to assess relative risk of HIV acquisition in vaccinees vs placebo recipients over time...
  6. pmc HIV-DNA priming alters T cell responses to HIV-adenovirus vaccine even when responses to DNA are undetectable
    Stephen C De Rosa
    Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA
    J Immunol 187:3391-401. 2011
    ....
  7. pmc Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine
    Nicole Frahm
    Vaccine and Infectious Disease Division and HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    J Clin Invest 122:359-67. 2012
    ..These findings provide what we believe to be a new understanding of how preexisting viral immunity may impact the efficacy of vaccines under current evaluation for prevention of HIV, tuberculosis, and malaria...
  8. pmc Immune-correlates analysis of an HIV-1 vaccine efficacy trial reveals an association of nonspecific interferon-γ secretion with increased HIV-1 infection risk: a cohort-based modeling study
    Yunda Huang
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America Public Health Science Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 9:e108631. 2014
    ..We assessed pre-infection cellular immune responses measured at 4 weeks after the second vaccination to determine their roles in HIV-1 infection susceptibility among Step study male participants...
  9. pmc Effect of rAd5-Vector HIV-1 Preventive Vaccines on HIV-1 Acquisition: A Participant-Level Meta-Analysis of Randomized Trials
    Yunda Huang
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS ONE 10:e0136626. 2015
    ..Rigorous meta-analysis can provide crucial information to advise the future utility of rAd5-vector vaccines...
  10. pmc New clinical trial designs for HIV vaccine evaluation
    Zoe Moodie
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Curr Opin HIV AIDS 8:437-42. 2013
    ....
  11. pmc Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans
    Samuel O Pine
    Program in Pathobiology, Department of Global Health, University of Washington, Seattle, Washington, United States of America
    PLoS ONE 6:e18526. 2011
    ..Together, these results suggest that vector-specific humoral responses may reduce vaccine-induced T-cell responses by previously undetected mechanisms...
  12. pmc Selection of HIV vaccine candidates for concurrent testing in an efficacy trial
    Ying Huang
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States Electronic address
    Curr Opin Virol 17:57-65. 2016
    ..We illustrate the selection approaches using data from HIV-1 vaccine trials. ..
  13. pmc Impact of herpes simplex virus type 2 on HIV-1 acquisition and progression in an HIV vaccine trial (the Step study)
    Ruanne V Barnabas
    Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 57:238-44. 2011
    ..To explore these relationships, we examined the impact of preexisting HSV-2 infection in an international HIV vaccine trial...
  14. pmc Vaccine-induced HIV-specific CD8+ T cells utilize preferential HLA alleles and target-specific regions of HIV-1
    David Friedrich
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    J Acquir Immune Defic Syndr 58:248-52. 2011
    ..Thus, HLA immunodominance plays a substantial role in vaccine-induced T-cell responses...
  15. pmc Role of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection
    Natalie N Zheng
    Department of Pathology, University of Washington, Seattle, WA 98195, USA
    J Virol 81:9061-71. 2007
    ..In conclusion, the T-cell memory responses associated with containment of single HIV-1 and HIV-2 infection play a similar significant role in the immune control of dual HIV-1 and HIV-2 infection...
  16. pmc Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination
    Helen Horton
    Program in Infectious Diseases, Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109, USA
    J Immunol Methods 323:39-54. 2007
    ..In conclusion, we provide the first description of a quantitatively validated ICS assay, which permits quantitative and qualitative evaluation of vaccine-induced immunogenicity and analysis of immune correlates of protection...
  17. pmc Power/sample size calculations for assessing correlates of risk in clinical efficacy trials
    Peter B Gilbert
    Vaccine and Infectious Disease and Public Health Sciences Divisions, Fred Hutchinson Cancer Research Center, Seattle, 98109, Washington, U S A
    Stat Med 35:3745-59. 2016
    ..We illustrate the methods with preventive HIV vaccine efficacy trials and include an R package implementing the methods. Copyright © 2016 John Wiley & Sons, Ltd. ..
  18. doi request reprint A case for preART-adjusted endpoints in HIV therapeutic vaccine trials
    Yunda Huang
    Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Department of Global Health, University of Washington, Seattle, WA, USA Electronic address
    Vaccine 34:1282-8. 2016
    ..We propose fold-change-based endpoints and report comparative analyses accounting for imbalanced preART VL and missing data...